Sec Form 3 Filing - Buckley Sean D. @ Fibrocell Science, Inc. - 2018-06-19

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 3
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Buckley Sean D.
2. Issuer Name and Ticker or Trading Symbol
Fibrocell Science, Inc. [ FCSC]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
See Remarks
(Last) (First) (Middle)
FIBROCELL SCIENCE, INC., 405 EAGLEVIEW BLVD
3. Date of Earliest Transaction (MM/DD/YY)
06/19/2018
(Street)
EXTON, PA19341
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock $ 232.5 ( 1 ) 01/14/2021 Common Stock 200 D
Option to Purchase Common Stock $ 82.35 ( 2 ) 07/19/2023 Common Stock 334 D
Option to Purchase Common Stock $ 63.6 ( 3 ) 04/01/2025 Common Stock 1,000 D
Option to Purchase Common Stock $ 11.25 ( 4 ) 09/27/2026 Common Stock 2,229 D
Option to Purchase Common Stock $ 11.25 ( 5 ) 03/16/2027 Common Stock 4,000 D
Option to Purchase Common Stock $ 3.45 ( 6 ) 01/25/2028 Common Stock 5,000 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Buckley Sean D.
FIBROCELL SCIENCE, INC.
405 EAGLEVIEW BLVD
EXTON, PA19341
See Remarks
Signatures
/s/ Sean D. Buckley 06/27/2018
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The option vested as follows: (i) 100 shares on January 14, 2011 and (ii) 50 shares on each of January 14, 2012 and January 14, 2013.
( 2 )The option vested in four equal installments on July 19, 2013, July 19, 2014, July 19, 2015 and July 19, 2016.
( 3 )The option vests in four equal installments on April 1, 2016, April 1, 2017, April 1, 2018 and April 1, 2019 provided the reporting person is employed by Fibrocell Science, Inc., (the "Company") on each vesting date.
( 4 )The option vests as follows (i) 558 shares on September 27, 2017 and (ii) the remaining shares in twelve equal quarterly installments beginning on December 27, 2017 and ending on September 27, 2020 provided the reporting person is employed by the Company on each vesting date.
( 5 )The option vests as follows: (i) 1,000 shares on March 16, 2018 and (ii) the remaining shares in twelve equal quarterly installments beginning on June 16, 2018 and ending on March 16, 2021 provided the reporting person is employed by the Company on each vesting date.
( 6 )The option vests as follows: (i) 1,250 shares on January 25, 2019 and (ii) the remaining shares in twelve equal quarterly installments beginning on April 25, 2019 and ending on January 25, 2022 provided the reporting person is employed by the Company on each vesting date.

Remarks:
Vice President of Business Administration and Corporate Secretary

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.